Professor of coronavaccine: The first nåleøjer is done

An american company has come to the last test of a possible coronavaccine.

Phase 3-the trial begins 27. July, and it is promising that the company Moderna is reached. The believe Jan Pravsgaard Christensen, who is a professor in the infektionsimmunologi of the University of Copenhagen.

- It means that the company has come through the first two nåleøjer, so the vaccine is safe, gives no side effects, and it can induce the immune response that should protect against the disease, he says.

A potential vaccine goes through three phases before eventually coming on the market. At the first stage, it is studied whether the product is dangerous for the people. It is not this, it goes on to the next phase. It makes the most.

In the second stage, it is tested whether the subjects develop either antibodies or so-called T-cells - both parts indicates that the product can give a positive effect. Here fail many products according to Jan Pravgaard Christensen.

- So, to go back to the desktop, and maybe start from scratch or at least modify its product significantly in order to get something out of it, he says.

A small group of products reaches to stage 3. The phase consists of the blindtest with two large groups of subjects. One group gets the product, while the other gets a placebo, in other words, a product without impact.

- In phase 3 it is studied whether the product actually has the effect you want. In other words, whether you can actually protect against being infected from the disease, or at least not get such a serious disease, as if one were not vaccinated, says Jan Pravsgaard Christensen.

When the groups have been respectively the product and the placebo, researchers examine whether those who have got the product, actually also is better protected against the virus, or at least get milder symptoms.

It is not a guarantee that the product ends up coming out on the market, although it has reached the final stage.

- There are many products where, in stage 3, discovers that it does not have the appropriate effect, " says the professor.

In some cases it turns out that only a small percentage of people that get the vaccine, are experiencing an effect. And so it will in most cases not make sense to go ahead with the product, because it becomes too difficult to sell.

The u.s. company Moderna stands to finish the experiment by 27. October 2022. It is expected, however, the results before then.

in Denmark, Too, are actors by developing possible coronavacciner. Both Statens Serum Institut and Copenhagen University in time, but it has not reached so far yet.